Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Laboratory Corp. of America Holdings (NYSE:LH) by 1.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,101 shares of the medical research company’s stock after buying an additional 202 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Laboratory Corp. of America were worth $2,667,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Quadrant Capital Group LLC lifted its holdings in shares of Laboratory Corp. of America by 13.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,138 shares of the medical research company’s stock worth $184,000 after acquiring an additional 132 shares during the last quarter. Rafferty Asset Management LLC bought a new stake in Laboratory Corp. of America in the fourth quarter worth about $444,000. National Asset Management Inc. boosted its position in shares of Laboratory Corp. of America by 70.5% during the fourth quarter. National Asset Management Inc. now owns 2,695 shares of the medical research company’s stock valued at $458,000 after buying an additional 1,114 shares during the period. MUFG Securities EMEA plc bought a new position in shares of Laboratory Corp. of America during the fourth quarter valued at approximately $9,710,000. Finally, Gideon Capital Advisors Inc. purchased a new stake in shares of Laboratory Corp. of America in the fourth quarter worth approximately $1,157,000. 89.81% of the stock is owned by hedge funds and other institutional investors.

Shares of Laboratory Corp. of America stock opened at $162.03 on Tuesday. The company has a market capitalization of $15.74 billion, a PE ratio of 50.16, a P/E/G ratio of 2.76 and a beta of 1.37. The company has a 50-day simple moving average of $169.76 and a two-hundred day simple moving average of $165.09. Laboratory Corp. of America Holdings has a one year low of $98.02 and a one year high of $196.36. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.07 and a current ratio of 1.18.

Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings data on Wednesday, April 29th. The medical research company reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.42. Laboratory Corp. of America had a net margin of 2.77% and a return on equity of 15.03%. The firm had revenue of $2.82 billion for the quarter, compared to the consensus estimate of $2.73 billion. During the same quarter in the previous year, the firm earned $2.62 EPS. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, equities analysts predict that Laboratory Corp. of America Holdings will post 9.69 earnings per share for the current fiscal year.

LH has been the topic of several research analyst reports. Deutsche Bank began coverage on Laboratory Corp. of America in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $210.00 price objective on the stock. Bank of America upped their price target on shares of Laboratory Corp. of America from $147.00 to $190.00 and gave the stock a “neutral” rating in a report on Thursday, April 30th. Barclays raised their target price on shares of Laboratory Corp. of America from $188.00 to $195.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. Wells Fargo & Co reiterated a “buy” rating on shares of Laboratory Corp. of America in a report on Wednesday, June 10th. Finally, Morgan Stanley increased their price objective on Laboratory Corp. of America from $241.00 to $244.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 20th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Laboratory Corp. of America currently has a consensus rating of “Buy” and an average target price of $202.18.

In other Laboratory Corp. of America news, EVP Der Vaart Sandra D. Van sold 872 shares of Laboratory Corp. of America stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $160.33, for a total value of $139,807.76. Following the transaction, the executive vice president now directly owns 4,915 shares of the company’s stock, valued at $788,021.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.70% of the stock is currently owned by insiders.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Recommended Story: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.